The effect of vildagliptin therapy on atherogenic postprandial remnant particles and LDL particle size in subjects with Type 2 diabetes

Diabetic Medicine

Volumn 30, Issue 6, 2013, Pages 756-757

  Matikainen, N ^a,b   Taskinen, M R ^b  

^a Department of Medicine   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ALOGLIPTIN; APOLIPOPROTEIN A5; APOLIPOPROTEIN B100; APOLIPOPROTEIN B48; EXENDIN 4; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; MONOUNSATURATED FATTY ACID; PLACEBO; POLYUNSATURATED FATTY ACID; SATURATED FATTY ACID; SITAGLIPTIN; VILDAGLIPTIN;

ATHEROGENESIS; CHOLESTEROL BLOOD LEVEL; DYSLIPIDEMIA; HUMAN; LETTER; LIPID DIET; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; TRIACYLGLYCEROL BLOOD LEVEL;

ADAMANTANE; BIOLOGICAL MARKERS; CHYLOMICRON REMNANTS; DIABETES MELLITUS, TYPE 2; DIET, HIGH-FAT; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS; HYPERGLYCEMIA; HYPERLIPIDEMIAS; HYPOLIPIDEMIC AGENTS; LIPOPROTEINS, LDL; MEALS; NITRILES; PARTICLE SIZE; POSTPRANDIAL PERIOD; PYRROLIDINES; TRIGLYCERIDES;

EID: 84878047441     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12094     Document Type: Letter

References (7)

1. Farr S, Adeli K. Incretin-based therapies for treatment of postprandial dyslipidemia in insulin-resistant states. Curr Opin Lipidol 2012; 23: 56-61.
2. Matikainen N, Manttari S, Schweizer A, Ulvestad A, Mills D, Dunning BE et al. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia 2006; 49: 2049-2057.
3. Tremblay AJ, Lamarche B, Deacon CF, Weisnagel SJ, Couture P. Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes. Diabetes Obes Metab 2011; 13: 366-373.
4. Eliasson B, Möller-Goede D, Eeg-Olofsson K, Wilson C, Cederholm J, Fleck P et al. Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study. Diabetologia 2012; 55: 915-925.
5. Vakkilainen J, Jauhiainen M, Ylitalo K, Nuotio IO, Viikari JS, Ehnholm C et al. LDL particle size in familial combined hyperlipidemia: effects of serum lipids, lipoprotein-modifying enzymes, and lipid transfer proteins. J Lipid Res 2002; 43: 598-603.
6. Bunck MC, Corner A, Eliasson B, Heine RJ, Shaginian RM, Wu Y et al. One-year treatment with exenatide vs. insulin glargine: effects on postprandial glycemia, lipid profiles, and oxidative stress. Atherosclerosis 2010; 212: 223-229.
7. Nolan CJ, Damm P, Prentki M. Type 2 diabetes across generations: from pathophysiology to prevention and management. Lancet 2011; 378: 169-181.